scholarly article | Q13442814 |
P50 | author | Homie Razavi | Q37391777 |
Vladimir P. Chulanov | Q56846666 | ||
Ezequiel Ridruejo | Q56846682 | ||
Robert Flisiak | Q56980311 | ||
Inka Aho | Q57304703 | ||
Waldemar Halota | Q63673102 | ||
Pagbajabyn Nymadawa | Q79298636 | ||
George Papatheodoridis | Q42284105 | ||
Carole Seguin-Devaux | Q42459569 | ||
Sarah Blach | Q42986595 | ||
Joël Mossong | Q47816839 | ||
Catherine Wendy Spearman | Q56245939 | ||
Chris Estes | Q56678759 | ||
Anil C Anand | Q56808420 | ||
P2093 | author name string | P Hoffmann | |
S Acharya | |||
C Henderson | |||
M Prins | |||
S R Shah | |||
A Rakhmanova | |||
Y Lurie | |||
P Puri | |||
R J de Knegt | |||
A Hatzakis | |||
C Bergin | |||
D Struck | |||
T Staub | |||
V Arendt | |||
H W Reesink | |||
S Norris | |||
V Sypsa | |||
F R Zuure | |||
O Baatarkhuu | |||
A C Gadano | |||
M O Silva | |||
K Barclay | |||
F Bessone | |||
G Choudhuri | |||
D Kershenobich | |||
Z Ben-Ari | |||
E Zuckerman | |||
I Schréter | |||
P Kristian | |||
P Arkkila | |||
A Mahomed | |||
M Leshno | |||
S Sokolov | |||
E Gane | |||
J Hornell | |||
R Safadi | |||
V Saraswat | |||
P Jarčuška | |||
D Houlihan | |||
K Tomasiewicz | |||
I Veldhuijzen | |||
K Souliotis | |||
S Radke | |||
M I Andersson | |||
A J van der Meer | |||
E A Croes | |||
E Gower | |||
A Shevaldin | |||
C R Brunton | |||
C Stedman | |||
D Davaadorj | |||
D van Santen | |||
E A Strebkova | |||
E Nurmukhametova | |||
F G Villamil | |||
I Shestakova | |||
J F Sanchez Avila | |||
J Oyunbileg | |||
J R Daruich | |||
K Kostrzewska | |||
K Razavi-Shearer | |||
L Cisneros | |||
L Undram | |||
M de Vree | |||
M Oltman | |||
M Sonderup | |||
N Blokhina | |||
N Mamonova | |||
N Mendez-Sanchez | |||
N Pimenov | |||
N Prabdial-Sing | |||
N R Dashdorj | |||
O Dalgard | |||
O Sagalova | |||
O Shibolet | |||
R Sanduijav | |||
S Hrusovsky | |||
S Willemse | |||
Ts Oyunsuren | |||
Y A Dahgwahdorj | |||
P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
Epidemiology of viral hepatitis and hepatocellular carcinoma | Q29617918 | ||
Evolving epidemiology of hepatitis C virus | Q29619973 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt | Q30403548 | ||
Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection | Q35824825 | ||
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 | ||
The changing epidemiology of hepatitis C virus infection in Europe | Q37006042 | ||
Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina | Q37221506 | ||
Trends and projections of hepatitis C virus epidemiology in Latin America. | Q37886279 | ||
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel | Q37886280 | ||
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | Q39213684 | ||
Seroprevalence and risk factors of hepatitis B and hepatitis C virus infections in uttarakhand, India | Q41258167 | ||
Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. | Q41744442 | ||
Strategies to manage hepatitis C virus (HCV) disease burden. | Q42226125 | ||
Hepatitis C virus seroprevalence in the Netherlands | Q42978867 | ||
Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study | Q42980207 | ||
Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality | Q42980230 | ||
Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India. | Q42981236 | ||
Predicted effects of treatment for HCV infection vary among European countries | Q42982945 | ||
Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey | Q42985162 | ||
Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. | Q42997217 | ||
HCV infection in Poland | Q43029694 | ||
Prevalence and risk factors of HCV infection in Poland | Q43041364 | ||
Hepatitis C virus infection in the general population: a community-based study in West Bengal, India | Q43049060 | ||
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). | Q43993163 | ||
Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum | Q44562896 | ||
Hepatitis C virus prevalence in The Netherlands: migrants account for most infections | Q45354905 | ||
Hepatitis C virus infection during pregnancy in North India | Q45531117 | ||
Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy | Q46146376 | ||
[Liver transplantation in Norway through 25 years]. | Q51139887 | ||
P921 | main subject | Hepatitis C virus | Q708693 |
P304 | page(s) | 6-25 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
P1476 | title | Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2 | |
P478 | volume | 22 Suppl 1 |
Q33918841 | A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound |
Q40528954 | A simple real-time polymerase chain reaction assay using SYBR Green for hepatitis C virus genotyping. |
Q92888058 | Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study |
Q52597014 | Approaches for simplified HCV diagnostic algorithms. |
Q31148392 | Attempt to calculate the prevalence and features of chronic hepatitis C infection in Tuscany using administrative data |
Q38637199 | Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents |
Q41925862 | Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs? |
Q38613271 | Direct-acting antiviral agents for HCV infection affecting people who inject drugs |
Q64068380 | Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals |
Q40092669 | Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? |
Q28074447 | Epidemiology of hepatitis C in Greece |
Q38946139 | Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization |
Q41562313 | Estimates on HCV disease burden worldwide - filling the gaps |
Q40932598 | Estimating HCV disease burden - volume 3 (editorial). |
Q47589992 | Estimating HCV disease burden-volume 4 (editorial). |
Q40228317 | Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study |
Q38772047 | Genotype 3 Infection: The Last Stand of Hepatitis C Virus |
Q30240220 | Global epidemiology and burden of HCV infection and HCV-related disease |
Q38839762 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study |
Q57166986 | Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework |
Q47594606 | Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis |
Q57030951 | Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir |
Q30235491 | Hepatitis C virus infection |
Q36924982 | Hepatitis C virus infection in Argentina: Burden of chronic disease. |
Q36269670 | Hepatitis C virus infection: Are there still specific problems with genotype 3? |
Q37620782 | Hepatitis C virus seroprevalence in the general female population of 9 countries in Europe, Asia and Africa |
Q45325255 | Historical epidemiology of hepatitis C virus in select countries—volume 4 |
Q37040556 | Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons |
Q92750665 | Innovative strategies for the elimination of viral hepatitis at a national level: A country case series |
Q38842781 | Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. |
Q40189279 | Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study |
Q47572592 | Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection |
Q38931620 | Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. |
Q37428608 | Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis |
Q36067623 | Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand |
Q97526372 | Prevalence of HBV and HCV infections, Bhutan, 2017: Progress and next steps |
Q29353552 | Prevalence, determinants and genetic diversity of hepatitis C virus in the multi-ethnic population living in Suriname |
Q92982844 | Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India |
Q38661825 | Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs |
Q41922681 | Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe |
Q55191989 | Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients. |
Q37102817 | Specific Age and Gender Prevalence of Hepatitis C Virus Infection in Iran |
Q91923463 | Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis |
Q38982103 | Tackling the Hepatitis C Disease Burden in Punjab, India |
Q37171340 | Viral hepatitis: Indian scenario |
Search more.